Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Buildings (2016 - 2019)

Myriad Genetics has reported Buildings over the past 5 years, most recently at $18.2 million for Q3 2019.

  • Quarterly Buildings fell 3.7% to $18.2 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $18.2 million through Sep 2019, down 3.7% year-over-year, with the annual reading at $18.8 million for FY2019, 2.59% down from the prior year.
  • Buildings was $18.2 million for Q3 2019 at Myriad Genetics, down from $18.8 million in the prior quarter.
  • Over five years, Buildings peaked at $20.5 million in Q1 2018 and troughed at $16.1 million in Q4 2016.
  • The 5-year median for Buildings is $18.2 million (2015), against an average of $18.2 million.
  • Year-over-year, Buildings fell 13.3% in 2017 and then grew 25.77% in 2018.
  • A 5-year view of Buildings shows it stood at $17.3 million in 2015, then dropped by 6.94% to $16.1 million in 2016, then grew by 22.98% to $19.8 million in 2017, then dropped by 4.55% to $18.9 million in 2018, then dropped by 3.7% to $18.2 million in 2019.
  • Per Business Quant, the three most recent readings for MYGN's Buildings are $18.2 million (Q3 2019), $18.8 million (Q2 2019), and $18.6 million (Q1 2019).